Liquidseq HRR Gene Panel [15 Genes] Test: Booking, Price, and Results
About Liquidseq HRR Gene Panel [15 Genes] Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | HRR Gene Panel, Homologous Recombination Repair Gene Panel, HRR 15-Gene Panel, Liquid Biopsy HRR Panel |
| Sample Type | Peripheral blood (Streck tube) |
| Fasting Required | No |
| Report Time | 30 days |
| Recommended For | Adults of all genders with breast, ovarian, pancreatic, or prostate cancer; those with a family history of hereditary cancers |
| Price | Starting at ₹24,000 |
What Is a Liquidseq HRR Gene Panel [15 Genes] Test?
The Liquidseq HRR Gene Panel [15 genes] test is a specialised genetic test that analyses 15 genes involved in the Homologous Recombination Repair (HRR) pathway. HRR is the process by which cells fix damaged DNA. Pathogenic variants in these genes may be associated with an increased risk of certain cancers and can help inform treatment decisions, including potential eligibility for targeted therapies in appropriate clinical settings.
The test uses liquid biopsy technology, meaning it is performed on a blood sample rather than a tumour tissue sample. It is also known as the HRR Gene Panel or Liquid Biopsy HRR Panel.
What Does a Liquidseq HRR Gene Panel [15 Genes] Test Measure?
The Liquidseq HRR Gene Panel [15 genes] test examines 15 genes that play a role in repairing damaged DNA. When any of these genes carry a mutation, the body's ability to fix DNA errors is reduced, which can lead to cancer development or affect how a cancer responds to treatment. The 15 genes covered are listed below, along with a brief explanation of each.
| Gene | Role in the Body |
|---|---|
| BRCA1 | Key DNA repair gene; mutations raise breast, ovarian, and other cancer risks |
| BRCA2 | Works with BRCA1 to repair DNA; mutations linked to multiple cancer types |
| ATM | Helps cells detect and respond to DNA damage |
| PALB2 | Works alongside BRCA1 and BRCA2 to maintain DNA stability |
| CHEK1 | Cell-cycle checkpoint kinase involved in the cellular response to DNA damage and maintenance of genomic stability |
| CHEK2 | Similar to CHEK1; regulates cell cycle progression |
| BRIP1 | Interacts with BRCA1 to assist DNA repair |
| CDK12 | Kinase involved in regulating the expression of genes important for DNA damage response and repair |
| RAD51B | Assists in DNA strand repair during homologous recombination |
| RAD51C | Involved in DNA repair using a matching DNA strand as a template |
| RAD51D | Supports the DNA repair process alongside other RAD51 proteins |
| RAD54L | Plays a role in strand invasion during DNA repair |
| BARD1 | Associated with BRCA1; involved in suppressing tumour growth |
| FANCL | Part of the Fanconi anaemia pathway, which helps repair DNA damage |
| PPP2R2A | Regulatory subunit of protein phosphatase 2A involved in cell signalling, cell-cycle regulation, and genomic stability |
Why Is a Liquidseq HRR Gene Panel [15 Genes] Test Done?
A doctor may order the Liquidseq HRR Gene Panel [15 genes] test to identify clinically relevant HRR gene alterations that may help assess hereditary cancer risk, guide treatment decisions, or provide additional genomic information in patients with certain cancers.
Common Symptoms That May Require This Test
The following indications are among the most common reasons a doctor may recommend this test.
- Personal history of breast, ovarian, pancreatic, or prostate cancer
- Family history of hereditary cancers across multiple generations
- Early-onset cancer diagnosed before the age of 50
- Bilateral breast cancer (cancer affecting both breasts)
- Male breast cancer diagnosis
- Multiple primary cancers in the same individual
- Suspected hereditary cancer syndrome based on clinical evaluation
Conditions This Test Can Help Detect
This test can help identify genetic changes linked to a range of conditions. These include:
- HRR pathway deficiency underlying breast, ovarian, pancreatic, or prostate cancers
- Eligibility for PARP inhibitor therapy (a type of targeted cancer treatment)
- Hereditary Breast and Ovarian Cancer (HBOC) syndrome
- Genetic alterations involving Fanconi anaemia pathway genes may be identified
How to Prepare and What to Expect
No special preparation is needed for the Liquidseq HRR Gene Panel [15 genes] test. The following sections explain what to do before the test and how the collection process works.
Do You Need to Fast?
No, fasting is not required for this test. You may eat and drink normally before your appointment.
Practical Tips Before Your Test
Keep the following points in mind before going for sample collection.
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test.
- Inform your doctor about any medications you are currently taking.
- Genetic counselling is strongly recommended before testing so you understand what the results may mean for you and your family.
- Carry previous cancer-related medical records and documented family history to your appointment.
Step-by-Step Procedure
The sample collection for the Liquidseq HRR Gene Panel [15 genes] test procedure is straightforward. Here is what to expect.
- A trained phlebotomist (blood collection specialist) will clean a vein in your arm and draw a small amount of blood.
- The blood is collected in a special Streck tube, which preserves cell-free DNA (cfDNA) fragments circulating in the bloodstream.
- The sample is stored under refrigeration (2 to 8 degrees Celsius) to maintain stability during transport.
- At the laboratory, the blood is processed to isolate cfDNA and other relevant components.
- The isolated DNA is analysed using Next-Generation Sequencing (NGS), which enables simultaneous evaluation of multiple genes for clinically relevant genetic variants.
- Results are reviewed by a specialist and the report is prepared within the stated turnaround time.
Factors That Can Affect Accuracy
Certain factors may affect how reliable the test results are. These include:
- Recent treatment, including chemotherapy or other systemic therapies, may influence the amount of circulating tumour DNA available for analysis
- Low tumour burden, meaning insufficient circulating tumour DNA for analysis
- Use of an incorrect blood collection tube (Streck tubes are specifically required)
- Delayed sample processing after collection
Understanding Your Liquidseq HRR Gene Panel [15 Genes] Test Results
This test does not produce numerical values. Instead, it reports whether mutations are present in the 15 HRR genes. The table below outlines the three possible result types.
| Result | Classification | What It Means |
|---|---|---|
| No pathogenic or likely pathogenic variant detected | Negative | No pathogenic or likely pathogenic variant was identified in the genes analysed; however, this does not completely exclude hereditary cancer risk or the presence of variants outside the scope of the test |
| Pathogenic or likely pathogenic variant detected | Positive | A clinically significant genetic alteration was identified. Depending on the specific variant and clinical context, this may be associated with hereditary cancer risk and/or eligibility for targeted therapies |
| Variant of uncertain significance present | Indeterminate (VUS) | A genetic change was identified, but its clinical significance is currently uncertain. Medical management decisions should generally not be based solely on a VUS finding. |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain situations can influence how results are interpreted.
- Recent chemotherapy may lower the amount of circulating tumour DNA in the blood, potentially affecting test sensitivity.
- If tumour burden is very low, there may be insufficient cfDNA for a conclusive result.
- Results from liquid biopsy and tumour tissue testing may occasionally differ because they evaluate different biological samples and may capture different aspects of tumour genetics.
How to Maintain Healthy Levels
Because this is a genetic test, the results reflect inherited or acquired genetic alterations and are not changed by lifestyle modifications. The following steps are recommended after receiving your results.
- Attend regular cancer screening appointments as advised by your oncologist.
- If a mutation is detected, discuss risk-reduction options with a genetic counsellor.
- Inform close family members about the availability of genetic testing, as inherited mutations may affect them as well.
Lupin Diagnostics Liquidseq HRR Gene Panel [15 Genes] Test Price
The Liquidseq HRR Gene Panel [15 genes] test cost starts at ₹24,000 at Lupin Diagnostics. This test requires a visit to a Lupin Diagnostics centre, as home collection is not available for this test.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 24000 |
| CHENNAI | 24000 |
| HYDERABAD | 24000 |
| KOLKATA | 24000 |
| NAVI MUMBAI | 24000 |
| PUNE | 24000 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book the Liquidseq HRR Gene Panel [15 genes] test online or at a centre.
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
The Liquidseq HRR Gene Panel [15 genes] test is a blood-based genetic test that analyses 15 genes involved in DNA repair. It uses liquid biopsy technology, which means no tissue biopsy is needed. The test helps detect hereditary cancer risk and guides decisions about targeted cancer treatment.
This test is recommended for individuals with a personal or family history of breast, ovarian, pancreatic, or prostate cancer. It is also ordered for cancer patients being evaluated for PARP inhibitor therapy, a type of targeted treatment that works specifically in tumours with HRR gene mutations.
A tissue biopsy involves removing a sample of tumour tissue through a surgical or needle procedure. A liquid biopsy, as used in this test, requires only a blood draw. The blood contains cell-free DNA fragments shed by tumour cells, which can be analysed without directly sampling the tumour itself.
A positive result indicating an HRR gene mutation may mean the patient is eligible for PARP inhibitor therapy. PARP inhibitors are approved treatments for BRCA-associated ovarian, breast, pancreatic, and prostate cancers. Your oncologist will advise on the most appropriate next steps based on your specific result.
Genetic counselling is strongly recommended both before and after the Liquidseq HRR Gene Panel [15 genes] test. The results can have significant implications for the patient and for blood relatives. A genetic counsellor can help explain what the findings mean, clarify variants of uncertain significance, and guide decisions about further testing or risk management.
If a pathogenic germline variant is identified, biological relatives may also carry the same variant and could benefit from discussing genetic counselling and testing with a healthcare professional. It is often advisable to test an affected family member first, as a confirmed mutation in that person allows for more meaningful testing of other relatives.
Liquidseq HRR Gene Panel [15 Genes] Test: Booking, Price, and Results
